{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:23:52Z","timestamp":1794029032585,"version":"4.8.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":217,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ghadvances.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastro Hep Advances"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.gastha.2026.101095","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:09:13Z","timestamp":1787065753000},"page":"101095","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rituximab as Salvage Therapy in Difficult-to-Treat Autoimmune Hepatitis: A Prospective Case Series"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3809-640X","authenticated-orcid":false,"given":"Craig","family":"Lammert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Blessing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaz","family":"Arif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Minnaganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Vuppalanchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naga","family":"Chalasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.gastha.2026.101095_bib1","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.31065","article-title":"Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases","volume":"72","author":"Mack","year":"2020","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.gastha.2026.101095_bib2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL Clinical Practice guidelines: autoimmune hepatitis","volume":"63","year":"2015","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.gastha.2026.101095_bib3","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/HEP.0000000000000589","article-title":"Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: first report of the IAIHG retrospective registry","volume":"79","author":"Slooter","year":"2024","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.gastha.2026.101095_bib4","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.jhep.2020.07.023","article-title":"Second-line and third-line therapy for autoimmune hepatitis: a position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group","volume":"73","author":"Lohse","year":"2020","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.gastha.2026.101095_bib5","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/j.cgh.2017.06.001","article-title":"Efficacy and safety of mycophenolate mofetil and tacrolimus as second-line therapy for patients with autoimmune hepatitis","volume":"15","author":"Efe","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.gastha.2026.101095_bib6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00281-022-00937-5","article-title":"B cells in autoimmune hepatitis: bystanders or central players?","volume":"44","author":"Schulthei\u00df","year":"2022","journal-title":"Semin Immunopathol"},{"issue":"7","key":"10.1016\/j.gastha.2026.101095_bib7","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/apt.16035","article-title":"Review article: experimental therapies in autoimmune hepatitis","volume":"52","author":"Halliday","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.gastha.2026.101095_bib8","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1159\/000322693","article-title":"A case of autoimmune hepatitis treated with rituximab","volume":"4","author":"Barth","year":"2010","journal-title":"Case Rep Gastroenterol"},{"issue":"11","key":"10.1016\/j.gastha.2026.101095_bib9","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.4067\/S0034-98872011001100015","article-title":"Successful rituximab therapy in refractory autoimmune hepatitis and Evans syndrome","volume":"139","author":"Carey","year":"2011","journal-title":"Rev Med Chil"},{"issue":"3","key":"10.1016\/j.gastha.2026.101095_bib10","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ajg.2013.08.009","article-title":"Rituximab for refractory autoimmune hepatitis: a case report","volume":"14","author":"Al-Busafi","year":"2013","journal-title":"Arab J Gastroenterol"},{"issue":"2","key":"10.1016\/j.gastha.2026.101095_bib11","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1542\/peds.2011-1900","article-title":"Successful treatment of refractory autoimmune hepatitis with rituximab","volume":"132","author":"D'Agostino","year":"2013","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.gastha.2026.101095_bib12","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jhepr.2019.10.005","article-title":"Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: results from the International Autoimmune Hepatitis Group","volume":"1","author":"Than","year":"2019","journal-title":"JHEP Rep"},{"issue":"9","key":"10.1016\/j.gastha.2026.101095_bib13","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1111\/liv.15970","article-title":"Rituximab is a safe and effective alternative treatment for patients with autoimmune hepatitis: results from the ColHai registry","volume":"44","author":"Riveiro-Barciela","year":"2024","journal-title":"Liver Int"},{"issue":"10206","key":"10.1016\/j.gastha.2026.101095_bib21","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomized placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.gastha.2026.101095_bib22","article-title":"Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis","volume":"2","author":"Arvaniti","year":"2020","journal-title":"JHEP Rep"},{"issue":"1","key":"10.1016\/j.gastha.2026.101095_bib14","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis","volume":"48","author":"Hennes","year":"2008","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.gastha.2026.101095_bib15","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jhep.2021.12.041","article-title":"Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group","volume":"76","author":"Pape","year":"2022","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.gastha.2026.101095_bib16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1155\/2013\/512624","article-title":"Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy","volume":"27","author":"Burak","year":"2013","journal-title":"Can J Gastroenterol"},{"issue":"8","key":"10.1016\/j.gastha.2026.101095_bib17","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/art.11181","article-title":"Serologic changes following B-lymphocyte-depleting therapy for rheumatoid arthritis","volume":"48","author":"Cambridge","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.gastha.2026.101095_bib18","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1136\/annrheumdis-2014-206605","article-title":"Rituximab for IgG4-related disease: a prospective, open-label trial","volume":"74","author":"Carruthers","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"19","key":"10.1016\/j.gastha.2026.101095_bib19","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.gastha.2026.101095_bib20","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.gastha.2026.101095_bib24","first-page":"1752","article-title":"Povetacicept, an enhanced dual APRIL\/BAFF antagonist for the treatment of lupus and other B-cell-related autoimmune diseases","volume":"75","author":"Evans","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.gastha.2026.101095_bib25","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease: a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"issue":"10416","key":"10.1016\/j.gastha.2026.101095_bib26","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"}],"container-title":["Gastro Hep Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572326002165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572326002165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:24:32Z","timestamp":1794025472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772572326002165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2772572326002165"],"URL":"https:\/\/doi.org\/10.1016\/j.gastha.2026.101095","relation":{},"ISSN":["2772-5723"],"issn-type":[{"value":"2772-5723","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab as Salvage Therapy in Difficult-to-Treat Autoimmune Hepatitis: A Prospective Case Series","name":"articletitle","label":"Article Title"},{"value":"Gastro Hep Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastha.2026.101095","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Gastroenterological Association Institute.","name":"copyright","label":"Copyright"}],"article-number":"101095"}}